NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer

Fudan University

Status and phase: Enrolling; Phase 3

Conditions: Metastatic Colorectal Cancer (CRC)

Treatments: Drug: NALIRIFOX plus targeted therapy; Drug: FOLFOX plus targeted therapy

Study type: Interventional

Funder types: Other

Identifiers

NCT07309289

CSPC-DEY-CRC-K10

Details and patient eligibility

About

To explore the safety and efficacy of NALIRIFOX plus targeted therapy versus FOLFOX plus targeted therapy as first-line treatment for metastatic colorectal cancer.

Full description

This is a multicentre, open-label, randomised study to explore the safety and efficacy of NALIRIFOX plus targeted therapy versus FOLFOX plus targeted therapy as first-line treatment for metastatic colorectal cancer.

Enrollment: 144 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• ≥18 years old
• Histopathologically confirmed patient with an inoperable metastatic colorectal adenocarcinoma
• The unresectable stage of metastatic disease has not received any systemic antitumor therapy
• For subjects previously receiving neoadjuvant or adjuvant therapy, the date of first discovery of disease progression must be at least 12 months removed from the date of last administration of neoadjuvant or adjuvant therapy
• The presence of at least 1 measurable lesion that can be evaluated according to the RECIST v1.1 criteria
• ECOG 0~1
• Normal bone marrow and organ function
• Understand the situation of this study, patients and/or legal representatives voluntarily agree to participate in this study and sign informed consent form

Exclusion criteria

• Patients with known MSI-H or dMMR who were evaluated by investigators as suitable for treatment with immune checkpoint inhibitors.
• Patients allergic to the investigational drug and its excipients
• Underweight (body mass index [BMI]<18.5 kg/m^2
• Known or suspected central nervous system metastasis
• Received irinotecan before enrollment
• Had undergone surgery and other oncologic treatments within the first 4 weeks of enrollment
• Previous treatment-related toxicity didn't return to NCI-CTCAE v5.0 class I or below.
• The use of CYP3A, CYP2C8, and UGT1A1 inhibitors or inducers couldn't be discontinued or were not discontinued within 2 weeks prior to enrollment
• Serious gastrointestinal disorders
• Interstitial lung disease
• Tendency of arterial embolism and massive bleeding within 6 months before enrollment (except surgical bleeding)
• Patients with fluid accumulation that couldn't reach a stable state and small amount of pleural effusion or ascites on imaging without clinical symptoms could be enrolled
• Intestinal obstruction, or a risk of intestinal obstruction in the short term
• Gastrointestinal perforation, intraperitoneal abscess, and fistula
• Any serious or uncontrolled systemic disease, including uncontrolled high blood pressure, heart disease, active bleeding, active viral infection, etc
• Have had other malignancies within the past 5 years or currently, except cured cervical carcinoma in situ, uterine carcinoma in situ, and non-melanoma skin cancer
• Patients of childbearing age who refuse to take contraceptives, women who are pregnant or breastfeeding
• The researchers didn't consider it appropriate to participate in this study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

144 participants in 2 patient groups

NALIRIFOX plus targeted therapy

Experimental group

Description:

NALIRIFOX plus targeted therapy

Treatment:

Drug: NALIRIFOX plus targeted therapy

FOLFOX plus targeted therapy

Active Comparator group

Description:

FOLFOX plus targeted therapy

Treatment:

Drug: FOLFOX plus targeted therapy